TY - JOUR
T1 - Long-term antipsychotic use, orthostatic hypotension and falls in older adults with Alzheimer’s disease
AU - NILVAD Study Group
AU - Dyer, Adam H.
AU - Murphy, Claire
AU - Dolphin, Helena
AU - Morrison, Laura
AU - Briggs, Robert
AU - Lawlor, Brian
AU - Kennelly, Sean P.
AU - Segurado, Ricardo
AU - Kennelly, Sean
AU - Olde, Marcel G.M.Rikkert
AU - Howard, Robert
AU - Bo¨rjesson-Hanson, Anne
AU - Tsolaki, Magda
AU - Lucca, Ugo
AU - William Molloy, D.
AU - Coen, Robert
AU - Riepe, Matthias W.
AU - Ka´lma´n, Ja´nos
AU - Cregg, Fiona
AU - O’Dwyer, Sarah
AU - Walsh, Cathal
AU - Adams, Jessica
AU - Banzi, Rita
AU - Breuilh, Laetitia
AU - Daly, Leslie
AU - Aisen, Paul
AU - Gaynor, Siobhan
AU - Sheikhi, Ali
AU - Taekema, Diana G.
AU - Verhey, Frans R.
AU - Nemni, Raffaello
AU - Franceschi, Massimo
AU - Frisoni, Giovanni
AU - Zanetti, Orazio
AU - Konsta, Anastasia
AU - Anastasios, Orologas
AU - Nenopoulou, Styliani
AU - Tsolaki-Tagaraki, Fani
AU - Pakaski, Magdolna
AU - Dereeper, Olivier
AU - Se´ne´chal, Olivier
AU - Devendeville, Agnès
AU - Calais, Gauthier
AU - Crawford, Fiona
AU - Mullan, Michael
AU - Aalten, Pauline
AU - Berglund, Maria A.R.N.
AU - Claassen, Jurgen A.
AU - Heus, Rianne A.
AU - Jong, Daan L.K.
N1 - Publisher Copyright:
© The Author(s), under exclusive licence to European Geriatric Medicine Society 2024..
PY - 2024/4
Y1 - 2024/4
N2 - Purpose: Antipsychotic use in Alzheimer disease (AD) is associated with adverse events and mortality. Whilst postulated to cause/exacerbate orthostatic hypotension (OH), the exact relationship between antipsychotic use and OH has never been explored in AD—a group who are particularly vulnerable to neuro-cardiovascular instability and adverse effects of medication on orthostatic blood pressure (BP) behaviour. Methods: We analysed longitudinal data from an 18-month trial of Nilvadipine in mild–moderate AD. We assessed the effect of long-term antipsychotic use (for the entire 18-month study duration) on orthostatic BP phenotypes measured on eight occasions, in addition to the relationship between antipsychotic use, BP phenotypes and incident falls. Results: Of 509 older adults with AD (aged 72.9 ± 8.3 years, 61.9% female), 10.6% (n = 54) were prescribed a long-term antipsychotic. Over 18 months, long-term antipsychotic use was associated with a greater likelihood of experiencing sit-to-stand OH (ssOH) (OR: 1.21; 1.05–1.38, p = 0.009) which persisted on covariate adjustment. Following adjustment for important clinical confounders, both antipsychotic use (IRR: 1.80, 1.11–2.92, p = 0.018) and ssOH (IRR: 1.44, 1.00–2.06, p = 0.048) were associated with a greater risk of falls/syncope over 18 months in older adults with mild–moderate AD. Conclusion: Even in mild-to-moderate AD, long-term antipsychotic use was associated with ssOH. Both antipsychotic use and ssOH were associated with a greater risk of incident falls/syncope over 18 months. Further attention to optimal prescribing interventions in this cohort is warranted and may involve screening older adults with AD prescribed antipsychotics for both orthostatic symptoms and falls.
AB - Purpose: Antipsychotic use in Alzheimer disease (AD) is associated with adverse events and mortality. Whilst postulated to cause/exacerbate orthostatic hypotension (OH), the exact relationship between antipsychotic use and OH has never been explored in AD—a group who are particularly vulnerable to neuro-cardiovascular instability and adverse effects of medication on orthostatic blood pressure (BP) behaviour. Methods: We analysed longitudinal data from an 18-month trial of Nilvadipine in mild–moderate AD. We assessed the effect of long-term antipsychotic use (for the entire 18-month study duration) on orthostatic BP phenotypes measured on eight occasions, in addition to the relationship between antipsychotic use, BP phenotypes and incident falls. Results: Of 509 older adults with AD (aged 72.9 ± 8.3 years, 61.9% female), 10.6% (n = 54) were prescribed a long-term antipsychotic. Over 18 months, long-term antipsychotic use was associated with a greater likelihood of experiencing sit-to-stand OH (ssOH) (OR: 1.21; 1.05–1.38, p = 0.009) which persisted on covariate adjustment. Following adjustment for important clinical confounders, both antipsychotic use (IRR: 1.80, 1.11–2.92, p = 0.018) and ssOH (IRR: 1.44, 1.00–2.06, p = 0.048) were associated with a greater risk of falls/syncope over 18 months in older adults with mild–moderate AD. Conclusion: Even in mild-to-moderate AD, long-term antipsychotic use was associated with ssOH. Both antipsychotic use and ssOH were associated with a greater risk of incident falls/syncope over 18 months. Further attention to optimal prescribing interventions in this cohort is warranted and may involve screening older adults with AD prescribed antipsychotics for both orthostatic symptoms and falls.
KW - Alzheimer disease
KW - Antipsychotic
KW - Dementia
KW - Falls
KW - Orthostatic hypotension
KW - Polypharmacy
UR - http://www.scopus.com/inward/record.url?scp=85181477846&partnerID=8YFLogxK
U2 - 10.1007/s41999-023-00910-x
DO - 10.1007/s41999-023-00910-x
M3 - Article
AN - SCOPUS:85181477846
SN - 1878-7649
VL - 15
SP - 527
EP - 537
JO - European Geriatric Medicine
JF - European Geriatric Medicine
IS - 2
ER -